Yes, schistosomiasis should be treated even after development of non-cirrhotic portal fibrosis
Treatment with praziquantel is indicated after development of non-cirrhotic portal fibrosis from schistosomiasis, as the primary goal is parasite eradication to prevent further egg deposition and ongoing inflammation, even though established fibrosis may not fully reverse 1.
Rationale for Treatment
The decision to treat is based on several key principles:
Primary Treatment Goals
- Parasite eradication remains the primary objective, which prevents continued egg deposition in portal venules and reduces ongoing granulomatous inflammation 1
- Egg burden reduction in patients with persistent infection decreases the risk of progressive hepatic fibrosis and limits community transmission 1
- Treatment prevents progression to more advanced disease stages, even when fibrosis is already present 2
Evidence on Fibrosis Regression
The evidence shows mixed but important outcomes:
- Mild to moderate hepatic fibrosis can reverse with successful treatment, as it results from immune response to schistosome eggs 1
- In one study, 32% of patients showed regression of periportal thickening four years after treatment with oxamniquine 3
- However, advanced fibrosis and portal hypertension are largely irreversible 1, and 68% of patients with established hepatosplenic disease may not show improvement in fibrosis 3
- Even when parasites are eradicated, portal fibrosis often persists 4
Post-Treatment Considerations
Multiple mechanisms contribute to persistent fibrosis progression even after treatment, including:
- Continued presence of viable Schistosoma eggs
- Co-infection with hepatitis viruses
- Alterations in splenic structure and function
- Disruption of intestinal mucosal barrier
- Hepatic ischemia and hypoxia
- Host genetic variations 2
Treatment Protocol
Praziquantel is the treatment of choice due to its efficacy, ease of administration, limited side effects, and low cost 1:
- Standard dose: 40 mg/kg administered orally as a single dose 5
- Most individuals clear infection with a single course
- Repeat dosing cures the majority of patients who fail initial eradication 1
Management of Established Portal Hypertension
Once non-cirrhotic portal fibrosis with portal hypertension has developed, manage portal hypertension according to guidelines for cirrhosis 6:
Variceal Bleeding Prevention
- Beta-blocker prophylaxis or endoscopic banding/sclerotherapy for variceal bleeding risk reduction 1
- Variceal bleeding is the primary cause of death in hepatic schistosomiasis 1
Surgical Considerations
- Selective shunts (distal splenorenal) or splenectomy with esophagogastric devascularization for recalcitrant bleeding 1
- Avoid non-selective shunts (proximal splenorenal or TIPS) as they carry higher risk of encephalopathy and hepatic impairment in schistosomiasis patients compared to cirrhosis, despite preserved hepatic synthetic function 1
Critical Pitfalls to Avoid
- Do not withhold treatment based on presence of established fibrosis—the goal shifts from reversal to prevention of progression
- Do not assume single treatment is sufficient—monitor for treatment failure and retreat as needed
- Do not use non-selective shunt procedures in advanced hepatic schistosomiasis due to risk of hepatic impairment despite normal synthetic function 1
- Screen for co-infections (hepatitis B/C) that may accelerate fibrosis progression 2
Diagnostic Confirmation
When schistosomiasis is suspected as a cause of non-cirrhotic portal fibrosis, schistosomiasis must be excluded before diagnosing idiopathic non-cirrhotic portal hypertension (INCPH) 6. Definitive diagnosis requires detecting schistosome eggs in stool or biopsy samples, as antibodies cannot differentiate active from past infections 5.